The acute-phase reactant C-reactive protein binds to phosphorylcholine- expressing Neisseria meningitidis and increases uptake by human phagocytes by Casey, R et al.
INFECTION AND IMMUNITY, Mar. 2008, p. 1298–1304 Vol. 76, No. 3
0019-9567/08/$08.000 doi:10.1128/IAI.00741-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
The Acute-Phase Reactant C-Reactive Protein Binds to
Phosphorylcholine-Expressing Neisseria meningitidis
and Increases Uptake by Human Phagocytes
Rosalyn Casey, Jane Newcombe, JohnJoe McFadden, and Katherine B. Bodman-Smith*
Division of Microbial Sciences, Faculty of Health and Medical Sciences, University of Surrey,
Stag Hill, Guildford, Surrey GU2 7XH, United Kingdom
Received 1 June 2007/Returned for modification 10 August 2007/Accepted 2 January 2008
Neisseria meningitidis is a global cause of meningitis and septicemia. Immunity to N. meningitidis involves
both innate and specific mechanisms with killing by serum bactericidal activity and phagocytic cells. C-reactive
protein (CRP) is an acute-phase serum protein that has been shown to help protect the host from several
bacterial pathogens, which it recognizes by binding to phosphorylcholine (PC) on their surfaces. Pathogenic
Neisseria species can exhibit phase-variable PC modification on type 1 and 2 pili. We have shown that CRP can
bind to piliated meningococci in a classical calcium-dependent manner. The binding of CRP to the meningo-
coccus was concentration dependent, of low affinity, and specific for PC. CRP appears to act as an opsonin for
N. meningitidis, as CRP-opsonized bacteria showed increased uptake by human macrophages and neutrophils.
Further investigation into the downstream effects of CRP-bound N. meningitidis may lead us to a better
understanding of meningococcal infection and help direct more effective therapeutic interventions.
Neisseria meningitidis is an important global pathogen which
causes meningitis (with mortality rates of 4 to 6%) and septic
shock (with mortality rates of up to 40%) (15). Successful
capsule-based vaccines against serogroup A and C strains of N.
meningitidis have been developed, but the serogroup B capsule
is poorly immunogenic, and cross-reactivity of anti-serogroup
B antibodies with host antigens has prevented the adoption of
a similar approach for serogroup B disease. The production of
a serogroup B vaccine has therefore become a priority in many
developed countries. N. meningitidis is carried harmlessly in the
nasopharynx by an estimated 10% of the world’s population
(36). In some individuals, however, virulent meningococci are
capable of attaching to epithelial cells, entering the cells by
phagocytosis, and accumulating within phagocytic vacuoles
(32). Multiplication of meningococci within the blood and at
secondary sites of infection, such as the meninges, pericar-
dium, and joints, causes systemic release of proinflammatory
cytokines, including interleukins 1 and 6 and tumor necrosis
factor alpha.
Immunity to N. meningitidis involves both innate and specific
mechanisms. Carriage of commensal strains of Neisseria can
elicit antibody responses that are cross-protective against
pathogenic meningococci. However, although bactericidal an-
tibodies can be protective, complement deficiencies can render
individuals more susceptible to meningococcal disease. For
example, individuals lacking components of the terminal mem-
brane attack complex are 1,000 to 10,000 times more likely to
develop disseminated meningococcal disease in their lifetime
than the general population (26). Moreover, the organism has
evolved several mechanisms to avoid clearance by a competent
complement system. These include the recruitment of factor
H, a negative regulator of the alternative pathway (28), and the
presentation of a polysaccharide capsule and sialylated lipo-
oligosaccharide (LOS), which can down-regulate activation of
the alternative pathway and inhibit formation of the membrane
attach complex (21). Additionally, absence of serum bacteri-
cidal activity does not always correlate with susceptibility (35);
thus, other mechanisms of protection, such as opsonization
and killing by phagocytic cells, have recently been considered
of increased importance, particularly with respect to serogroup
B disease.
C-reactive protein (CRP) has long been recognized as a key
player in the innate response to pathogenic infection and has
been suggested to play a possible role in linking innate and
acquired immune responses (41). This ancient member of the
pentraxin family was discovered in 1930 as a serum protein that
precipitated with the cell wall C polysaccharide of Streptococ-
cus pneumoniae (34). CRP has since been shown to bind to
several microorganisms within the respiratory tract and
is thought to be involved in inflammatory diseases such as
arthritis and atherosclerosis. CRP is a pentameric molecule
with two faces: a recognition face, which binds to ligands on
apoptotic cells, cell debris, and several microorganisms, and a
reverse effector face, which facilitates interaction with host
receptors, such as Fc receptors (31). These two functional
faces allow CRP to recognize pathogens and damaged host
cells and to facilitate their removal by recruiting the comple-
ment cascade and phagocytic cells. No CRP deficiency states
have been identified in humans, suggesting that the protein is
crucial to survival. However, at least 31 single-nucleotide poly-
morphisms have been identified for the human CRP gene (10).
One recent study on three single-nucleotide polymorphisms
within the CRP gene found polymorphisms that were associ-
ated with increased mortality in bacteremic patients (14). Al-
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lelic polymorphisms in the FcRII CRP receptors also occur
and may be associated with the severity of meningococcal dis-
ease (7). CRP may have a role in meningococcal infections, as
higher serum CRP levels are found in patients admitted to
hospitals with meningococcal disease than patients suffering
from viral infections (6).
The principal ligand for CRP is phosphorylcholine (PC),
which is found on the cell wall teichoic acids of S. pneumoniae
(9), the LOS of Haemophilus influenzae, and the surface of
Pseudomonas aeruginosa (17), Proteus morganii, and Aspergillus
fumigatus (22). The expression of PC by pathogens appears to
be critical for colonization of the human respiratory tract, and
although it may help pathogens colonize the nasopharynx, it
can also increase CRP-mediated serum killing of bacteria in
human sera and increase antibody-mediated serum resistance
in mice (8, 39). There have been no reports on the binding of
CRP to pathogenic Neisseria species, although binding be-
tween CRP and PC motifs on the LOS of commensal species
such as Neisseria lactamica and Neisseria subflava has been
demonstrated (29). Unlike the commensal species, pathogenic
Neisseria species do not express PC on their LOS, but the
epitope is phase-variably expressed on both the class I and
class II pili (38). In this report, we confirm the presence of PC
on a piliated serogroup B strain of N. meningitidis and dem-
onstrate that CRP binds to this strain in a concentration-
dependent, calcium-dependent manner. We also explore the
biological consequences of this binding in terms of the uptake
of N. meningitidis by human professional phagocytes.
MATERIALS AND METHODS
CRP purification. Purified (97%) human CRP was purchased from The
Binding Site and further purified by affinity column chromatography based on
the method detailed by Volanakis et al. (37). The purified CRP was dialyzed
repeatedly in phosphate-buffered saline (PBS) to remove traces of Tris-buffered
saline and sodium azide, and purity was confirmed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. Re-
combinant human CRP (Calbiochem) was also used in noncellular assays. Re-
combinant CRP was produced in Escherichia coli as a nonglycosylated
polypeptide chain with a molecular mass of 115 kDa and the same amino acid
sequence as native human CRP (40). The recombinant protein was purified by
Calbiochem by PC affinity chromatography and was determined to be pure by
SDS-PAGE analysis. The product contained 9 ng/ml LPS as determined by the
Limulus assay.
Bacterial culture. The serogroup B meningococcal strain C311 and a sponta-
neous nonpiliated mutant, C311p, were kindly donated by Mumtaz Virji, Uni-
versity of Bristol. An isolate of H44/76 containing the green fluorescent protein
(GFP)-expressing plasmid pEG2 was gratefully received from Myron
Christodoulides, University of Southampton (11). This plasmid is a hybrid shuttle
vector containing the red-shifted gfp gene under the control of a porA promoter
and has been modified by replacing the ampicillin resistance cassette (bla) with
an erythromycin resistance cassette (ermC), resulting in pEG2-Ery (M.
Christodoulides, unpublished data). The GFP-containing plasmid was harvested
from strain H44/76 using a standard kit (Qiagen) and transformed into strain
C311. Strains were stored frozen in Mueller-Hinton broth (MHB; Oxoid) with
15% glycerol and subcultured onto Columbia blood agar plates (Columbia agar
base [Oxoid] supplemented with 5% [vol/vol] defibrinated horse blood [TC
Supplies]). Plates were incubated at 35°C with 5% CO2 for 18 to 24 h and then
used to inoculate MHB at an optical density at 595 nm of 0.02. Cultures were
shaken at 125 rpm at 35°C for 4 h for use in experiments (with the exception of
time course studies).
Cell culture. The premonocytic cell lines THP-1 and U937 were obtained from
the European Collection of Cell Cultures and maintained in complete RPMI
medium containing 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM L-
glutamine, and 10% heat-inactivated fetal bovine serum (all from Invitrogen).
For differentiation into adherent macrophages, THP-1 cells were seeded at 4 
105/ml (400 l/well) in eight-well plastic chamber slides (Nunc) in medium
containing 10 nM phorbol myristate acetate (PMA; Sigma-Aldrich) for 72 h prior
to experiments. Similarly, U937 cells were seeded at 2  105/ml and were
differentiated with 10 nM PMA for 72 h and 100 nM vitamin D3 and 100 nM
retinoic acid (both from Sigma-Aldrich) for 24 h.
Preparation of human monocyte-derived macrophages and granulocytes. Pe-
ripheral blood was extracted from healthy consenting volunteers in accordance
with local research ethical committee guidelines. Mononuclear cells were sepa-
rated using Histopaque 1077 as per the manufacturer’s instructions (Sigma-
Aldrich). Peripheral blood mononuclear cells (PBMCs) were seeded at 3 
106/ml in eight-well plastic chamber slides in RPMI without serum and positively
selected for by plastic adherence. Adherent cells were cultured for 7 days in
complete RPMI, and macrophage-like morphology was examined by light mi-
croscopy. Granulocytes were separated from blood using Polymorphoprep as per
the manufacturer’s instructions (Axis-Shield). Granulocytes were seeded at 2 
107/ml in chamber slides in RPMI without serum and positively selected for by
plastic adherence.
CRP binding studies. Bacteria were grown in MHB for 4 h, spun at 1,000 
g for 15 min, fixed in 4% paraformaldehyde (PFA) for 2 h, spun at 2,000  g for
2 min, and resuspended in RPMI at an optical density at 595 nm of 5.00. Bacteria
were used at an optical density of 5 because this density demonstrated the
maximum differential for CRP binding between calcium-rich and calcium-de-
pleted conditions during dose-response experiments (data not shown). A CRP
binding assay was developed based on a method developed for Leishmania
donovani (12). Briefly, 50-l aliquots of culture were dispensed onto 96-well
Nunc Maxisorp microtiter plates alongside RPMI-only controls. Plates were
dried overnight in an incubator at 35°C, and the dried wells were blocked with
1% bovine serum albumin (Sigma-Aldrich) in PBS for 1 h. Wells were washed
with PBS, and 25 l of a given treatment was added to each well in triplicate.
Treatments were prepared in PBS and included PBS only, 10 mM EDTA, and
PC-calcium salt at various concentrations (Sigma-Aldrich). CRP was conjugated
to alkaline phosphatase (AP) using glutaraldehyde in a standard one-stage pro-
cedure (1). CRP-AP was diluted to 20 g/ml in PBS plus 1 mM CaCl2 and added
in 25-l volumes to wells. Plates were incubated in the dark for 2 h and then
washed three times with PBS and once with 0.1 M bicarbonate buffer (pH 9.6).
Plates were developed with 50 l/well p-nitrophenyl phosphate (pNPP; Sigma-
Aldrich) at 1 mg/ml in 0.1 M bicarbonate buffer (pH 9.6) containing 2 mM
MgCl2. Plates were incubated in the dark for a further hour and read at 405 nm
with a reference wavelength of 490 nm on a microplate reader (Biotek).
For time course binding studies, the CRP-binding assay used cultures har-
vested between 2 and 10 h incubation. For saturation experiments the assay was
carried out with a range of concentrations of CRP-AP. Competitive-inhibition
assays used the original concentration of CRP-AP with added PC-calcium salt
(Sigma-Aldrich) diluted in PBS at a range of concentrations. Calcium depen-
dency assays used bacteria dried on plates in bicarbonate buffer instead of RPMI
to reduce background calcium levels, and CRP-AP was added with 10-fold
dilutions of CaCl2 or no added calcium.
Analysis of PC expression. Cultures of piliated C311 and the nonpiliated
mutant C311p were grown in MHB, washed, and resuspended in sample buffer
every 2 h over a 10-h time course. Cell lysates were subjected to SDS-PAGE
through a 5% stacking gel and 12% resolving gel. Gels were blotted onto
polyvinylidene fluoride membranes (Roche) and probed with anti-PC antibody
(TEPC-15; Sigma-Aldrich). Equal loading of samples was confirmed by Coo-
massie-R staining of replicate gels. After washing, blots were incubated with
peroxidase-conjugated anti-mouse immunoglobulin A (Sigma-Aldrich). The
blots were developed on Kodak film using the Luminex system (Roche) and
photographed using a Gene Genius bioimaging system, and densitometry of
bands was performed using GeneTools software (Synoptics).
Incubation of phagocytes with N. meningitidis. Bacteria were grown for 4 h in
MHB, fixed for 2 h in 4% PFA, washed, and resuspended in PBS containing 10
mM CaCl2 to a concentration of approximately 8 108 bacteria per ml. Bacteria
were then treated for 30 min with equal volumes of heat-inactivated pooled
normal human serum (Sigma-Aldrich), 50 g/ml purified CRP, or PBS. Treated
bacteria were then added to phagocytes at a concentration equivalent to a
multiplicity of infection of 200 bacteria per cell and incubated at 37°C and 5%
CO2. Macrophages were incubated with bacteria for 2 h, and granulocytes were
incubated with bacteria for 20 min only. Wells were washed four times with PBS
and fixed with 1% PFA, and slides were mounted with Vectashield soft-set
mounting medium containing propidium iodide (Vecta Labs) for examination
using a confocal fluorescent microscope (Zeiss LSM 510). At least 100 cells from
10 randomly selected fields of view were analyzed for enumeration of phagocytes
colocalized with at least one bacterium and counts of total bacteria and total
phagocyte numbers per field of view. The presence of internalized bacteria was
confirmed by staining macrophages postinfection with a lipophilic membrane dye
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(FM 4-64FX; Molecular Probes) as per the manufacturer’s instructions and
mounting in Vectashield soft-set mounting medium without propidium iodide.
This allowed a z stack of images to be taken through the depth of the cell.
Statistical analyses. All experiments were performed in duplicate or triplicate
and repeated at least three times. Data analysis was performed by Student’s
paired t test using GraphPad Prism 4.1 software. A P value of 0.05 was
considered significant.
RESULTS
CRP binds to piliated N. meningitidis during early log-phase
growth. CRP binding to N. meningitidis strain C311 was mea-
sured over a 10-h time course. CRP binding was observed in
the presence of calcium after 2 h and peaked at 4 h of growth.
Binding then rapidly decreased to negligible levels by 8 h and
remained low up to the final 10-h time point (Fig. 1).
The maximum CRP binding at the 4-h time point corre-
sponds to early log phase in the growth curve of N. meningitidis
C311 in MHB. At 6 h, growth of N. meningitidis was still
exponential but CRP binding was almost halved. No CRP
binding was observed in the absence of calcium.
CRP binding to N. meningitidis requires the presence of pili
and calcium. As optimum CRP binding to piliated N. menin-
gitidis was observed after 4 h growth in MHB, the binding assay
was repeated at this time point, and the result was compared to
CRP binding to a spontaneous nonpiliated mutant of the same
strain (C311p). Negligible CRP binding of either strain was
observed in the absence of calcium (Fig. 2a), whereas in the
presence of calcium, the piliated strain bound significantly
more CRP than the nonpiliated mutant (P 0.011). There was
no significant difference in the binding of CRP to nonpiliated
C311p in the presence or absence of available calcium. To
confirm that CRP binding to the piliated strain was dependent
on the presence of calcium rather than the absence of EDTA,
CRP was incubated with the meningococcus with no added
CaCl2 or increasing concentrations of CaCl2 up to the normal
0.5 mM concentration (Fig. 2b). CRP binding increased with
calcium concentration and was significantly higher with the
standard 0.5 mM CaCl2 than either no CaCl2 or 0.005 mM
CaCl2 (P  0.029 and P  0.031, respectively).
CRP binding to N. meningitidis correlates with PC expres-
sion and is inhibited by free PC. Probing for PC expression in
a Western blot of whole-cell lysates from N. meningitidis grown
from 2 to 10 h showed that PC was not expressed in the
nonpiliated strain at any point during this time course, whereas
PC was detected in the piliated strain at all time points tested
(Fig. 3). PC expression was compared semiquantitatively by
densitometry and showed maximum expression after 4 h of
growth, the time point that gave maximum CRP binding. PC
expression dropped by a factor of more than 2.5 between 4 and
6 h of growth and remained low for the remaining time points.
The CRP binding assay was used with increasing concentra-
tions of soluble PC to assay for competitive inhibition. PC
concentrations below 1 M did not inhibit binding of CRP-AP
to piliated meningococci, but concentration-dependent inhibi-
tion was demonstrated above 5 M (Fig. 4). At a PC concen-
FIG. 1. Time course of CRP binding to piliated N. meningitidis
C311. Piliated C311 cells were grown in MHB, dried on microtiter
plates, and probed with CRP-AP in the presence of calcium (squares)
or EDTA (triangles). Plates were washed thoroughly, and the remain-
ing CRP-AP was detected by adding pNPP substrate and measuring
the optical density at 405 nm with a reference wavelength of 490 nm.
The dashed line is the growth curve of the cultures measured by optical
density. Data are the means from four replicate experiments 	 stan-
dard deviations.
FIG. 2. CRP binding to piliated and nonpiliated N. meningitidis in
the presence or absence of calcium. (a) Cells of the piliated strain C311
(solid bars) and nonpiliated mutant C311p (open bars) were dried on
microtiter plates and incubated with CRP-AP with 0.5 mM CaCl2
(calcium rich) or 0.5 mM CaCl2 with 10 mM EDTA (calcium de-
pleted). Plates were washed thoroughly, and bound CRP-AP was de-
tected by adding pNPP substrate and measuring the optical density at
405 nm with a reference wavelength of 490 nm. (b) The calcium
dependency of CRP binding to the piliated strain was confirmed by
repeating the experiment without added calcium alongside 10-fold
dilutions of the standard 0.5 mM CaCl2. Data are expressed as the
mean absorbances from six replicate experiments plus standard errors
of the mean (*, P  0.05).
FIG. 3. PC expression by piliated N. meningitidis with time. N.
meningitidis C311 (squares) and C311p (triangles) were grown in
broth culture and harvested at 2-h intervals for detection of PC by
PAGE and immunoblotting for PC expression with monoclonal anti-
body TEPC-15. The blot was captured digitally, and densitometry was
performed to quantify relative expression of PC. Data are from one
representative experiment.
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tration of 20 M, 50% inhibition was observed, and the inhib-
itory effect was saturated at PC concentrations above 100 M.
CRP binding to N. meningitidis is concentration dependent
and of low affinity. The affinity of binding between CRP and
piliated N. meningitidis was investigated by saturation binding
experiments. CRP-AP was added at increasing concentrations
to microtiter plates coated with a constant number of menin-
gococci, and the binding was measured (expressed as a per-
centage of the value recorded for 10 g/ml CRP-AP to over-
come interplate and interday variation of the assay). As can be
seen from Fig. 5a, CRP binding to N. meningitidis was concen-
tration dependent and began to plateau at 20 g/ml, whereas
CRP concentrations below 1 g/ml did not show detectable
binding to immobilized meningococci. Scatchard analysis of
CRP saturation binding allowed the dissociation constant (Kd)
to be estimated as 2.18  104 M (Fig. 5b).
CRP opsonization of N. meningitidis increases uptake of
meningococci by a macrophage-like cell line and peripheral
blood-derived macrophages and granulocytes. The piliated N.
meningitidis strain C311, which expresses GFP, was used to
monitor uptake of N. meningitidis by the PMA-differentiated
monocytic cell lines THP-1 and U937 and by human peripheral
blood-derived macrophages. Confocal fluorescence micros-
copy revealed an increased association of CRP-opsonized N.
meningitidis with peripheral blood-derived macrophages com-
pared to unopsonized bacteria (Fig. 6a and b). Subsequent
z-stack analysis of membrane-stained macrophages confirmed
that bacteria had been internalized by macrophages, as green
meningococci could be seen within the cell wall boundary (Fig.
6c). Increased association and uptake of CRP-opsonized me-
ningococci were also observed for the THP-1 macrophages,
although not for U937 cells.
Enumeration of bacterium-containing macrophages re-
vealed that significantly more differentiated THP-1 macro-
phages and donor-derived macrophages were associated with
meningococci when the bacteria were opsonized with CRP
(P  0.045 and P  0.019, respectively) (Fig. 6d). However, no
significant increase in the number of differentiated U937 mac-
rophages associated with meningococci was observed with
CRP opsonization (P  0.485) (Fig. 6d). The mean number of
bacteria per macrophage was significantly higher for CRP-
opsonized bacteria than unopsonized bacteria incubated with
THP-1 and donor-derived macrophages (P  0.014 and P 
0.013, respectively). For U937 cells, the increase in bacteria per
macrophage seen with CRP opsonization was not statistically
significant (P  0.112).
Human peripheral blood-derived granulocytes were incu-
bated with the GFP-expressing piliated N. meningitidis strain
C311 with or without CRP opsonization. Opsonization with
CRP significantly increased the uptake of N. meningitidis by
granulocytes in terms of both the percentage of cells associated
with bacteria and the mean number of bacteria per cell (Fig. 7a
and b) (P  0.0478 and P  0.013).
DISCUSSION
Our data demonstrate that CRP binds to N. meningitidis and
that this binding is dependent on the presence of calcium and
is likely to be dependent on the expression of PC by the pili of
the bacterium. The affinity of binding between CRP and the
meningococcus was estimated at 2.18  104 M. This binding
was found to have biological relevance, as the opsonization of
FIG. 4. PC inhibition of CRP binding to N. meningitidis. Piliated
meningococci were dried on enzyme-linked immunosorbent assay
plates and incubated with CRP-AP at a constant concentration of 10
g/ml with soluble PC at a range of concentrations. Data are means
from three replicate experiments 	 standard deviations.
FIG. 5. Concentration dependency and affinity of CRP binding to N. meningitidis. Piliated meningococci were dried on microtiter plates and
incubated with CRP-AP at a range of concentrations. (a) CRP binding was calculated as a percentage of standard absorbance at 405 nm. Data are
means from three replicate experiments 	 standard deviations. (b) Saturation binding data were used to plot a binding curve of specific binding
versus CRP concentration and a Scatchard plot (inset). Nonlinear regression of the binding curve was performed using GraphPad Prism 4.1, and
Kd was calculated from the graph as 2.18  10
4 M. Data are means of triplicate data from one representative experiment.
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PC-expressing N. meningitidis with CRP resulted in increased
uptake of the bacteria by macrophages and neutrophils.
Purified human CRP bound to immobilized piliated menin-
gococci of strain C311 but did not bind to the nonpiliated
mutant of the same strain, suggesting that the interaction is
pilus dependent. This was supported by Western blot analysis
of whole-meningococcal-cell lysates, in which CRP was found
to bind exclusively to a single band of protein, which was the
only band that could be labeled with the SM-1 antipilus anti-
body (data not shown). These data, therefore, strongly suggest
that the pilus is critical for CRP binding to N. meningitidis.
Further confirmation of this could be achieved by examining
CRP binding to meningococcal mutants with deliberately in-
activated pilin genes.
CRP did not bind to the meningococcus in the absence of
calcium, and binding increased with the concentration of
added calcium, suggesting that the binding was calcium depen-
dent, as is typically seen between CRP and PC. In subsequent
10-h growth curve experiments, PC expression correlated with
the level of CRP binding, strongly suggesting PC as the target
for CRP on the meningococcus. As described above, the neg-
ative control strain for PC expression used in these assays was
a natural nonpiliated mutant, making it possible that the fail-
ure of this isolate to bind CRP might be due to non-pilus-
associated (uncharacterized) changes to the surface of the bac-
terium. This is, however, highly unlikely, since CRP binding to
the meningococcus was shown to be PC-dependent (in our
inhibition studies) and Western blotting of N. meningitidis with
an anti-PC antibody detected binding only to a single pilus-
associated protein (38). In addition, a panel of 64 pathogenic
FIG. 6. Uptake of CRP-opsonized and nonopsonized N. meningitidis by macrophages. Representative microscope images of PBMC-derived
macrophages incubated with unopsonized GFP-expressing meningococci (a) and CRP-opsonized GFP-expressing meningococci (b) are shown.
Macrophages were stained red with propidium iodide postinfection (a and b), or macrophage membranes were stained with a fluorescent lipophilic
dye postinfection to enable z stacking through the macrophage to reveal internalized bacteria (c). (d and e) Enumeration of the association of
bacteria with macrophages was carried out on at least 100 cells from 10 randomly selected fields of view for CRP-opsonized bacteria (cross-hatched
bars) and unopsonized bacteria (stippled bars) colocalized with THP-1, U937, and peripheral blood-derived macrophages. The percentage of
macrophages associated with bacteria was calculated (d) as well as the mean number of adherent or intracellular bacteria per macrophage (e). Data
are means from at least three replicate experiments plus standard deviations (, P  0.05; nsd, no statistical difference).
FIG. 7. Uptake of N. meningitidis by granulocytes. GFP-expressing
C311 cells were grown, fixed in PFA, washed, and opsonized with CRP
(cross-hatched bars) or incubated with PBS (stippled bars) before
incubation with granulocytes adhered to plastic chamber slides. Slides
were washed, fixed, and stained with propidium iodide, and at least 100
cells from 10 randomly selected fields of view were counted for enu-
meration of the percentage of granulocytes associated with bacteria (a)
and the mean number of adherent or intracellular bacteria per gran-
ulocyte (b). Data are means from three replicate experiments plus
standard deviations (, P  0.05).
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Neisseria strains were screened for the presence of the PC
epitope, and only the pilin subunits of class I- and class II-
piliated strains were positive for PC expression (29). It is,
therefore, highly likely that the nonpiliated strain was unable
to bind CRP because it lacked pili and thereby the PC modi-
fication of pilus.
Both PC expression and CRP binding peaked at 4 h, coin-
ciding with the early log phase of growth, but decreased there-
after, dropping to negligible levels in late log phase. This
pattern of PC expression could be due to direct changes in PC
expression or changes in the degree of piliation of the bacteria
and is the focus of further investigation. In addition, PC ex-
pression can vary with microenvironments within the host.
Weiser et al. tested 31 isolates from blood, cerebrospinal fluid,
and throat cultures and found that PC expression was lower in
N. meningitidis isolates taken from blood than isolates from
other sites (38). The cause of these differences in PC expres-
sion is unknown, but growth rate-related variation of PC ex-
pression may be important in immune responses to N. menin-
gitidis, as growth rates may vary in different niches within the
host. Further evidence that CRP binding was PC specific was
provided by competition experiments, in which the addition of
soluble PC inhibited CRP binding to meningococci in a dose-
dependent fashion, with 50% inhibition observed at 20 M PC.
Several studies have highlighted an increase in circulating
CRP levels during infectious disease, with CRP levels in bac-
teremic patients reported as 10 to 100 g/ml, compared to less
than 10 g/ml in noninfected controls (16, 24). Our saturation
binding assay revealed that CRP binding to N. meningitidis was
concentration dependent, with binding being negligible below
1 g/ml and starting to plateau at 100 g/ml, well within the
clinical range expected during a bacterial infection. Saturation
binding experiments were used to estimate the binding affinity
of CRP for N. meningitidis (Kd  2.18  10
4 M). This affinity
was low compared to the affinity of CRP for PC itself (esti-
mated as 1.8  107 M by capillary electrophoresis [20]) and
for other organisms, such as L. donovani (which has a Kd of
1011 M [13]). L. donovani, however, is an intracellular para-
site which has evolved to utilize the opsonic properties of CRP
to increase uptake into human macrophages (13) without in-
creasing activation or killing ability of the cells (4). In contrast,
N. meningitidis is an extracellular pathogen and would not be
expected to benefit from increased uptake into macrophages,
where phagocytosis classically results in clearance of the bac-
teria. For this reason, a lower affinity of binding is not unex-
pected.
Our experiments indicated that CRP-opsonized N. meningi-
tidis cells were more readily taken up by macrophages than
unopsonized bacteria. This was the case for the cell line THP-1
and for peripheral blood monocyte-derived macrophages from
human donors and resulted in an increase in the percent of
macrophages associated with bacteria and the mean number of
bacteria per macrophage. Due to the limits of the experimental
procedure used, bacteria cannot be confirmed as truly intra-
cellular; thus, the phagocytic index was not stated in these
experiments. CRP has been shown to increase uptake of op-
sonized particles via FcRI, FcRIIa, and FcRIIb (2, 3, 5),
and work is currently under way to see if the enhanced uptake
observed in our experiments is due to Fc receptor binding.
The finding that the immortalized cell line U937 did not show
increased association with CRP-opsonized meningococci was
possibly due to differences in the state of activation or expres-
sion of cell surface receptors. The cells lines U937 and THP-1
were selected for these experiments because they have both
been reported to express FcRI and FcRII receptors, but
phenotypic differences obviously exist between different cell
lines. For example, the expression profile of known or putative
NF-
B target genes in response to LPS stimulation in U937
cells is much less similar than THP-1 cells to PBMC-derived
macrophages (30).
CRP opsonization of piliated N. meningitidis resulted in a
small but significant increase in uptake by human granulocytes.
This increase was much smaller than the effect of CRP opso-
nization on uptake by human macrophages. This difference is
likely to be due to the much shorter incubation time used for
granulocytes but may also be influenced by the scarcity of
FcRI receptors on neutrophils, which constitutively express
FcRII and FcRIII but require activation for the upregu-
lation of FcRI expression. Additionally, CRP binding to
FcRIIa has been shown to be dependent upon clustering of
CRP molecules upon the surface of particles such as erythro-
cytes or S. pneumoniae (K. Bodman-Smith, unpublished data).
It is likely, therefore, that scantily opsonized particles such as
N. meningitidis may show poor uptake via the FcRIIa of
granulocytes.
CRP binding could be a help or a hindrance to meningo-
coccal pathogenesis, and other CRP-binding organisms pro-
vide interesting comparisons when this question is considered.
CRP binding helps L. donovani to gain access to macrophages
without increasing killing of the organism (4) but has been
shown to protect mice from fatal infection with S. pneumoniae
(25). Murine studies of CRP function are, however, of limited
use due to incompatibilities between human CRP and some
mouse complement components (33) and the fact that CRP is
not a prototypic acute-phase protein in mice. The closely re-
lated pentraxin serum amyloid P is CRP’s counterpart in the
mouse and has been shown to bind to N. meningitidis in vitro
(27). Interestingly, rather than acting as an opsonin to increase
phagocyte uptake of the organism, serum amyloid P binding of
N. meningitidis actually decreases phagocytosis by neutrophils,
enhancing virulence of the organism.
CRP may also play a role in mucosal immunity, since it is
present in human nasal secretions and since CRP gene expres-
sion has been detected in epithelial cells from nasal polyps and
in pharyngeal cell lines (19). Mucosal CRP can bind to PC on
the surface of H. influenzae and S. pneumoniae and prevent
PC-mediated attachment to epithelial cells via the platelet-
activating factor receptor (18). It would be interesting to see
what effect CRP has on meningococcal attachment to respira-
tory epithelial cells. We hypothesize that CRP bound to the
pilus of the meningococcus could mask the pilus tip adhesin
PilC and thereby diminish binding to epithelial cells via
the putative pilus receptor CD46 (23).
In conclusion, we propose a potential role for CRP in the
immune response to meningococcal infection. Exploring the
downstream immunological consequences of CRP binding to
the meningococcus will enable us to better understand menin-
gococcal pathogenesis and may give cause to evaluate the po-
tential use of CRP in therapeutic interventions to meningo-
coccal disease.
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